Navigation Links
Novartis Phase III Study Shows ACZ885 Helped Substantially Reduce Steroid Use in 45% of Patients With Serious Form of Childhood Arthritis
Date:11/6/2011

EAST HANOVER, N.J., Nov. 7, 2011 /PRNewswire/ -- Novartis announced today new pivotal Phase III data showing 45% of children with active systemic juvenile idiopathic arthritis (SJIA) were able to substantially reduce their use of oral corticosteroids (often described as steroids) within 28 weeks of commencing treatment with ACZ885 (canakinumab) (p<0.0001)[1].

The results of the study, which met both primary endpoints, will be presented on November 9th at the American College of Rheumatology's (ACR) Annual Scientific Meeting in Chicago, US[1].

"The treatment of SJIA is a challenge given our current treatment options. Despite our best efforts, optimal disease control is often times elusive. We still must use steroids in the treatment of these children with SJIA. Steroids help manage many SJIA symptoms, such as fever and inflammation, but doctors try to minimize their use because of the potential negative impact on bones and growth," said Daniel Lovell, M.D., one of the study investigators and Professor of Pediatrics at the Cincinnati Children's Hospital Medical Center. "These data are exciting because they show that patients on ACZ885 were able to reduce their steroid use, and also experienced excellent disease control."

In addition, patients with SJIA on ACZ885 were nearly three times (0.37 hazard ratio) less likely to suffer a new flare. Therefore, only 27% of ACZ885-treated patients experienced a new flare, vs. 75% of patients on placebo during the study (p=0.0043)[1].

Data from this trial supports the safety and efficacy profile of ACZ885 in the study population. These results, along with data from a second pivotal study, are planned to form the basis for worldwide regulatory submissions in 2012. Side effects observed in this study were similar to those already seen for ACZ885's approved indication, including infections and neutropenia[1]. In addition, cases of macrophage activation syndrome (MAS) were reported in this study[1]
'/>"/>

SOURCE Novartis
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Cequent Pharmaceuticals Meets Novartis Option Fund Milestone; Continues to Next Phase to Validate Inflammatory Bowel Disease Targets in Vivo
2. Former Scientific Director at Genomics Institute of Novartis Research Foundation Named President of Cell Therapeutics Europe
3. Nektar Sells Pulmonary Business to Novartis For $115 Million and Nektar Retains Key Pulmonary Programs Including Amikacin Inhale, Inhaled Vancomycin, and Ciprofloxacin Inhalation Powder
4. Nektar Announces Closing of Sale of Specific Pulmonary Delivery Assets to Novartis for $115 Million
5. Physicians in Europe Rate Novartis #1 on Service Delivery, While Merck Earns Top Honors in the US
6. Novartis/Schering-Ploughs Drug Will Replace AstraZenecas Symbicort as Decision Resources Clinical Gold Standard by 2012 for the Treatment of Asthma
7. Schering-Plough Announces Changes to its Global Collaboration with Novartis to Develop Combination Therapies for Asthma and COPD
8. Photo: Novartis Receives FDA Approval for Valturna(R), a Single-Pill Combination of valsartan and aliskiren, to Treat High Blood Pressure
9. Heptares Therapeutics Announces Agreement With Novartis Option Fund to Apply its StaR(TM) Technology and Generate Novel Drug Leads Against a GPCR Target
10. Novartis Class Awarded $250 Million in Punitive Damages
11. Silence Therapeutics Partner Quark Signs Exclusive Option Agreement With Novartis for Development and Commercialisation of QPI-1002
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... August 29, 2014 Local veterinarian, Dr. ... Hospital are seeking candidates to participate in an investigational ... The ultimate goal of this study is to ... into one or two arthritically affected joints can help ... , Candidates for the current investigational study must be ...
(Date:8/29/2014)... Antonio, TX (PRWEB) August 29, 2014 ... and ISO 13485:2003 certified, GAMP® 5 compliant imaging ... awarded an international Phase II clinical trial to ... lymphoma. , Throughout this trial, Intrinsic Imaging will ... not limited to, protocol and charter development, site ...
(Date:8/28/2014)... “This kit has an improved extraction efficiency and ... 150 ppb,” said Mark Tess, PhD, Mycotoxin Product Manager for ... owners and USDA-GIPSA inspection agencies that have a need to ... place in a matter of minutes with nothing but our ... feed and grain before accepting it, but they no longer ...
(Date:8/28/2014)... PA (PRWEB) August 28, 2014 The ... create a culture that will allow individuals to perform ... becoming increasingly important for employers looking to compete in ... industries are embracing this trend, as the sector increasingly ... of a company, which will have real results on ...
Breaking Biology Technology:Burnt Hills Veterinary Hospital Seeks Candidates for an Investigational Study of Stem Cells for Dogs with Arthritis 2Intrinsic Imaging Awarded Phase II Clinical Trial to Assess New Treatment for Non-Hodgkin’s Lymphoma 2Klein Hersh International Leads Philadelphia Area Life Science Industry in Company Culture 2Klein Hersh International Leads Philadelphia Area Life Science Industry in Company Culture 3
... product ideas to market, RESEARCH TRIANGLE PARK, N.C., ... to $1 million in loans under,a program unveiled this ... loans are part of an expanded program funded by ... give early-stage,companies a boost before they become competitive for ...
... Nargis, a category 3 tropical storm that struck the low-lying and ... Agriculture Service (FAS) of the U.S. Department of Agriculture (USDA) began ... damaged agricultural areas to accompany its commodity intelligence reports. , ... ...
... July 9 Brinks Hofer Gilson & Lione, one of ... opening,of a new office in the Raleigh/Durham, North Carolina area ... T. Elliott, who will be,based in the Raleigh office. Mr. ... the firm as partners. The office will officially,be open for ...
Cached Biology Technology:N.C. Biotech Center Launches Larger Loans 2Myanmar's Cyclone-Damaged Rice Production Regions Monitored with GIS 2Myanmar's Cyclone-Damaged Rice Production Regions Monitored with GIS 3Brinks Hofer Gilson & Lione Expands to High-Tech Raleigh/Durham Area; Adds Accomplished Patent Attorneys to Its New Office 2Brinks Hofer Gilson & Lione Expands to High-Tech Raleigh/Durham Area; Adds Accomplished Patent Attorneys to Its New Office 3
(Date:8/31/2014)... past several decades, malaria diagnosis has changed very little. After ... the blood across a glass slide, stains it with a ... parasite, which causes the disease. This approach gives an accurate ... an important measure of disease severity but is not ... research team from the Singapore-MIT Alliance for Research and Technology ...
(Date:8/29/2014)... Scientists at the Barshop Institute for Longevity and Aging ... UT Health Science Center at San Antonio, have found ... longest-lived rodent, the naked mole rat. , They ... mole rats protects and alters the activity of the ... , The factor also protects proteasome function in human, ...
(Date:8/29/2014)... climatic shifts over the last 120,000 years may ... team of researchers led by City College of ... new biodiversity metric called "phylogeographic endemism." , It ... within species is restricted in geographical space. , ... 14 other researchers from institutions in Brazil, Australia ...
Breaking Biology News(10 mins):A new way to diagnose malaria 2A new way to diagnose malaria 3Factor in naked mole rat's cells enhances protein integrity 2CCNY team defines new biodiversity metric 2
... , Simultaneous targeting of two different molecules in cancer ... and stop metastasis, scientists at the University of California, ... effectiveness of combination treatments that include drugs like Avastin. ... a type of cancer known as neuroendocrine pancreatic tumors, ...
... German . Hydrofluorocarbons (HFCs), which have been ... CFCs, are also climatically very active and many are also ... international team of researchers recommends that the most potent of ... side effect of the Montreal Protocol for the global climate. ...
... affects the air, it also seeps under the asphalt and ... chemist at the University of the Basque Country (UPV/EHU), has ... impact of the metals emitted by cars. Likewise, he has ... and for this purpose has taken samples from roadsides in ...
Cached Biology News:Cancer therapy more potent when it hits 2 targets 2Cancer therapy more potent when it hits 2 targets 3Protecting the climate by reducing fluorinated greenhouse gas emissions 2Protecting the climate by reducing fluorinated greenhouse gas emissions 3Car tracks beyond the asphalt 2Car tracks beyond the asphalt 3
... 1) Persistent Analysis Environment 2) Dot ... etc. 3) Software Compensation 4) Cell ... Kinetics Platform 7) Intelligent batch generation of ... smoothing 9) Single drag-and-drop operations to perform ...
... Todays advanced protein cross-linking techniques are defined ... Dr. Shan S. Wong. This valuable hardcover ... schemes and current application references. More than ... protein cross-linking and conjugate preparation from ...
Schneider's Drosophila - Insect medium...
... easy operation of a wide range of ... software is fully secure and compliant with ... regulations, and compatible with user-created macros for ... use in high-level research and development as ...
Biology Products: